Genzyme Wins Restrictions On Generic Arthritis Drug Price
Law360, New York (January 5, 2012, 8:43 PM EST) -- Genzyme Corp. has won a preliminary injunction in its infringement suit against Seikagaku Corp. over osteoarthritis knee pain treatment Synvisc-One, setting a minimum price at which the Japanese pharmaceutical maker can sell its lower-cost generic, Genzyme announced Thursday.
Pending trial, Seikagaku will be allowed to sell the recently approved Gel-One generic product, but not for less than $547.60 per unit, the average market price for Genzyme's drug, according to the order.
"In the absence of injunctive relief directed at the defendants' pricing of the Gel-One product, the plaintiff will suffer irreparable harm from such marketing or sale," U.S. District Judge Douglas...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!